ARQT.US Arcutis Biotherapeutics Inc

Healthcare Biotechnology USA Stocks
28.26 USD
Close of Nov 14, 2026
19.30 34.80
Market cap
USD 3.57B
P/E
122.9x
P/B
14.27x
ROE
6.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ARQT.US undervalued?

Graham number

The Graham number of Arcutis Biotherapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arcutis Biotherapeutics Inc fundamental analysis

No fundamental analysis for Arcutis Biotherapeutics Inc yet.

Arcutis Biotherapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company …

Full company profile